Core Viewpoint - A patent dispute between two biopharmaceutical companies, HAPO (和铂医药-B) and Baiaosaitu (百奥赛图-B), has sparked significant discussion in the industry and impacted their market valuations. HAPO recently secured a major contract worth up to $620 million based on its antibody technology, while the patent dispute centers around HAPO's claims of patent infringement by Baiaosaitu regarding antibody technology [1][2]. Company Overview - HAPO, founded in 2016, acquired a Dutch biotechnology company to obtain its fully human antibody transgenic mouse platform, HarbourMice, which is now a core asset. The ongoing patent case involves the only heavy chain antibody (HCAb) technology from this platform [2][4]. - Baiaosaitu, established in 2009, initially focused on gene-edited mice and has developed a reputation for its PD-1 humanized mice, which are used in antibody development. The company has transitioned to antibody discovery and has seen significant revenue growth [3][4]. Patent Dispute Details - The patent dispute began in September 2024 when HAPO accused Baiaosaitu of infringing on its "combining molecule" patent related to the production of fully human heavy chain antibodies [4][6]. - The global market for antibody drugs has surpassed $200 billion, with the technology in question being considered a "chip-level" technology in biomedicine [1][5]. Market Position and Financials - HAPO has not yet launched any drugs but has achieved profitability through business development partnerships, with potential transaction values exceeding $5.5 billion since 2022 [2][3]. - Baiaosaitu's antibody business revenue reached 318 million yuan in 2024, reflecting over 80% year-on-year growth, with seven of the top ten global pharmaceutical companies as clients [3][6]. Technical Aspects of the Dispute - The dispute centers on the methods of producing heavy chain antibodies, with HAPO using a method that knocks out the light chain, while Baiaosaitu employs a silencing technique. The core issue is whether these methods are equivalent [9][10]. - There are only six companies globally with fully human heavy chain antibody mouse platforms, highlighting the competitive landscape [6]. Legal Proceedings - Following the lawsuit, Baiaosaitu has taken steps to challenge the jurisdiction of the Shanghai Intellectual Property Court and has sought to invalidate HAPO's patent [10][11]. - The Chinese biopharmaceutical sector is experiencing a surge in patent applications, indicating a potential increase in related legal disputes in the future [11].

Core Viewpoint - The patent dispute between Heptares Therapeutics and Baidu Biotech has intensified following a decision by the National Intellectual Property Administration of China to uphold Heptares' core patent related to fully human heavy chain antibodies, which supports Heptares' claims against Baidu's RenNano platform [1][2]. Group 1: Patent Dispute Details - On June 5, the National Intellectual Property Administration decided to maintain the validity of Heptares' core patent (patent number: CN201210057668.0), which is crucial for the production of fully human heavy chain antibodies using transgenic animals [1]. - Baidu Biotech's founder publicly expressed confusion and frustration regarding Heptares' legal actions, questioning why Heptares did not pursue similar technology platforms like RenMab and RenLite [1][2]. - Baidu Biotech announced plans to evaluate legal options to defend its rights, emphasizing that previous jurisdictional challenges were procedural and that the substantive case has yet to be heard [1]. Group 2: Broader Industry Implications - The patent battle reflects deeper issues within China's innovative pharmaceutical industry, highlighting the critical importance of intellectual property protection amid rapid industry growth [2]. - Heptares is also involved in ongoing patent litigation in the U.S. against Teneobio, which was acquired by Amgen for $2.5 billion, indicating the complexities and challenges faced by Chinese pharmaceutical companies in global intellectual property rights enforcement [2]. - The situation raises questions about balancing the protection of essential technologies with maintaining an open and cooperative industry ecosystem, as well as defining the boundaries between reasonable protection and excessive monopolization [2].

和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 法律程序的進展 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團知識產權保護工作的最新進展。 本公司董事會（「董事會」）欣然宣佈，針對百奧賽圖（北京）醫藥科技股份有限公 司（「百奧賽圖」）就本公司「結合分子」專利權（專利號：CN201210057668.0，「專 利」）提出的無效宣告請求，國家知識產權局依據《中華人民共和國專利法》第22條 第3款、第26條第3款、第26條第4款及第33條之規定，於2025年6月5日作出審查 決定：維持該專利權有效（「決定」）。該專利涉及一種利用轉基因動物製備全人源 僅重鏈抗體（「HCAb」）的方法。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 和鉑醫藥控股有限公司 主席兼執行董事 王勁松博士 香港 ...